Navigation Links
PDI Reports 2011 Fourth Quarter and Year End Financial Results
Date:3/7/2012

omic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause PDI's actual results to be materially different from those expressed or implied by any forward-looking statement. For example, with respect to statements regarding projections of future revenues, growth and profitability, actual results may differ materially from those set forth in this release based on the loss, early termination or significant reduction of any of our existing service contracts, the failure to meet performance goals in PDI's incentive-based arrangements with customers or the inability to secure additional business. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's subsequently filed Annual Report on Form 10-K for the year ended December 31, 2011 and current reports on Form 8-K. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

(Tables to Follow)

PDI, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)($ in thousands, except per share data)Three Months EndedYears EndedDecember 31,December 31,2011201020112010Revenue, net

$
38,283$
42,251$
57,291$
34,589Cost of services

29,58234,161124,820108,037Gross profit

8,7018,09032,47126,552Compensation expense

4,5444,65619,69416,267Other selling, general and administrative expenses

3,7055,34114,5901
'/>"/>

SOURCE PDI, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Full Year 2011 Results
2. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
3. Stereotaxis Reports 2011 Financial Results; Provides 2012 Milestones
4. ZONARE Reports Fourth Quarter and 2011 Results
5. IRIDEX Reports 2011 Fourth Quarter and Year-End Results
6. Cumberland Pharmaceuticals Reports 2011 Annual Financial Results
7. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
8. Angeion Corporation Reports First Quarter Fiscal Year 2012 Operating Results
9. ERT Reports Fourth Quarter and Full Year 2011 Operating Results
10. Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Global public relations leader Porter Novelli today announced that ... Prix Galien USA Awards, which recognize excellence in biopharmaceutical ... condition. Porter Novelli will be responsible for raising awareness ... of submissions. The Prix Galien is ...
...   - Jayex , ... the Trust to , Instantly Review ... , Delivery of High-Quality Patient,Centred Care ... technology specialist, http://www.jaxex.com today,announces that United Lincolnshire NHS Trust (ULHT) has,selected ...
Cached Medicine Technology:Porter Novelli Named Agency of Record for Prix Galien USA Awards 2United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk 2
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... Oregon State University researcher has found a relationship between ... of autism spectrum disorder in very young children. ... to show a direct relationship between motor skills and ... motor skills should be included in treatment plans for ... professor in OSU,s College of Public Health and Human ...
(Date:4/24/2014)... scientist at the University of York reveals that a ... of the nervous system may also play a pivotal ... research team, led by Dr Will Brackenbury, a Medical ... York, has studied how voltage-gated sodium channels assist in ... in the membranes of excitable cells, such as neurons, ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... LAKE FOREST, Ill. and MINNEAPOLIS , ... Fitness Corporation (NYSE AMEX: FIT ) today announced that ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in ...   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , On January 21, 2010 , ...
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... ... San Francisco,s famed PIER 39 docks, was successfully rescued, rehabilitated and released back to the ... assembled at Rodeo Beach in the Marin Headlands, Sausalito, CA to watch as "Abagnale" made ... ...
... focus of new laws, online testing and Super Bowl plug ... improve treatment of concussions in youth sports are making headway ... in scholastic sports will get big play Sunday at Super ... can help athletic trainers and doctors determine when it,s safe ...
... LOS ANGELES , Feb. 5 Food 4 ... to support children,s hospitals in the communities its stores serve in ... Chicago area. In addition, the supermarket chain,s Foods Co ... California . , Customers and team members can support their ...
... Finding may further understanding of common diseases, researchers say , ... map of areas of the human genome that control which ... a finding that may advance understanding of the genetic ... the human genome is uncharted territory -- entire stretches of ...
Cached Medicine News:Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:Concussion Awareness for Young Athletes Gets Big Play 2Health News:Food 4 Less Charitable Campaign to Benefit Children's Hospitals 2
... a vacuum tube for the collection, transport ... immunophenotyping by flow cytometry. The preservative contained ... the white blood cell cluster of differentiation ... Patient samples collected in Cyto-Chex BCT are ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
... reagent manufactured for the simultaneous quantitative ... cells. Streck-Lysing Agent IIIC is for ... S Plus II, III, IV, V, ... JT Series. The shelf life is ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Medicine Products: